BRPI0817334A8 - Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados - Google Patents
Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuadosInfo
- Publication number
- BRPI0817334A8 BRPI0817334A8 BRPI0817334A BRPI0817334A BRPI0817334A8 BR PI0817334 A8 BRPI0817334 A8 BR PI0817334A8 BR PI0817334 A BRPI0817334 A BR PI0817334A BR PI0817334 A BRPI0817334 A BR PI0817334A BR PI0817334 A8 BRPI0817334 A8 BR PI0817334A8
- Authority
- BR
- Brazil
- Prior art keywords
- gallisepticum
- bacteria
- live attenuated
- mycoplasma gallisepticum
- composition
- Prior art date
Links
- 241000204022 Mycoplasma gallisepticum Species 0.000 title abstract 9
- 230000002238 attenuated effect Effects 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102100038910 Alpha-enolase Human genes 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 abstract 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 abstract 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 abstract 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract 1
- 102000017528 Ribosomal protein L35 Human genes 0.000 abstract 1
- 108050005789 Ribosomal protein L35 Proteins 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 abstract 1
- 238000000575 proteomic method Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/35—Mycoplasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
BACTÉRIA MYCOPLASMA GALLISEPTICUM ATENUADAS VIVA, COMPOSIÇÃO PARA VACINA, USO DA DITA COMPOSIÇÃO E PROCESSO PARA IDENTIFICAÇÃO DE CLONES MYCOPLASMA GALLISEPTICUM ATENUADOS. A presente invenção refere-se a bactérias Mycoplasma gallisepticum atenuadas vivas que exibem expressão reduzida de uma proteína identificada como MGA_0621. Em certas modalidades, as bactérias atenuadas podem exibir adicionalmente a expressão reduzida de uma ou mais proteínas selecionadas do grupo que consiste em piruvato desidrogenase, fosfopiruvato hidratase, 2-desoxirribose-5-fosfato aldolase e proteína ribossomal L35, em relação a uma bactéria M. gallisepticum do tipo selvagem. São também fornecidas vacinas e processos de vacinação que envolvem o uso das bactérias M. gallisepticum atenuadas vivas e processos para a produção de bactérias M. gallisepticum atenuadas vivas. É fornecido um exemplo de cepa de M. gallisepticum atenuada viva, denominada MGx+47, que foi mostrada através de análise proteômica para exibir expressão significativamente reduzida de MGA_0621 e foi mostrado que era segura e eficaz quando administrada como uma vacina contra infecção por M. gallisepticum em frangos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99344707P | 2007-09-11 | 2007-09-11 | |
| PCT/US2008/010630 WO2009035644A1 (en) | 2007-09-11 | 2008-09-10 | Attenuated mycoplasma gallisepticum strains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0817334A2 BRPI0817334A2 (pt) | 2015-03-24 |
| BRPI0817334A8 true BRPI0817334A8 (pt) | 2016-03-29 |
Family
ID=40024216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0817334A BRPI0817334A8 (pt) | 2007-09-11 | 2008-09-10 | Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US7935356B2 (pt) |
| EP (2) | EP2200640B1 (pt) |
| JP (2) | JP5451619B2 (pt) |
| KR (2) | KR20120014041A (pt) |
| CN (1) | CN101896195B (pt) |
| AR (1) | AR068418A1 (pt) |
| AU (1) | AU2008299913B2 (pt) |
| BR (1) | BRPI0817334A8 (pt) |
| CA (1) | CA2699410C (pt) |
| CL (1) | CL2008002675A1 (pt) |
| CO (1) | CO6260102A2 (pt) |
| ES (1) | ES2437593T3 (pt) |
| ME (1) | ME00982B (pt) |
| MX (1) | MX2010002866A (pt) |
| NZ (1) | NZ583829A (pt) |
| PL (1) | PL2200640T3 (pt) |
| RU (1) | RU2441909C2 (pt) |
| TW (1) | TW200918666A (pt) |
| UA (1) | UA98506C2 (pt) |
| WO (1) | WO2009035644A1 (pt) |
| ZA (1) | ZA201001740B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200918666A (en) * | 2007-09-11 | 2009-05-01 | Wyeth Corp | Attenuated mycoplasma gallisepticum strains |
| US20090068231A1 (en) * | 2007-09-11 | 2009-03-12 | Wyeth | Live attenuated mycoplasma strains |
| UY32570A (es) * | 2009-04-24 | 2010-11-30 | Boehringer Ingelheim Vetmed | Vacuna viva modificada de mycoplasma bovis mejorada |
| EP2571980A4 (en) * | 2010-05-19 | 2014-02-26 | Bioproperties Pty Ltd | METHOD RELATED TO A WEAKEN MYCOPLASMA |
| CN102168073B (zh) * | 2010-11-30 | 2013-03-20 | 瑞普（保定）生物药业有限公司 | 一种提高疫苗生产中鸡毒支原体增殖能力的方法 |
| CN103074246B (zh) * | 2012-08-31 | 2015-09-02 | 南京天邦生物科技有限公司 | 一种低血清高效培养鸡毒支原体弱毒株培养基及其制备方法 |
| CN107446859B (zh) * | 2017-09-02 | 2020-12-18 | 河南省农业科学院畜牧兽医研究所 | 一株鸡毒支原体及其应用 |
| CN112159479B (zh) * | 2020-10-15 | 2022-03-22 | 福建农林大学 | 一种鸡毒支原体多抗原表位融合蛋白pMG-mEA及其应用 |
| CN114045298B (zh) * | 2021-09-09 | 2023-10-20 | 武汉科前生物股份有限公司 | 一种鸡滑液囊支原体亚单位疫苗及制备方法及应用 |
| CN114973312A (zh) * | 2022-04-28 | 2022-08-30 | 广西宏廷智能科技有限公司 | 一种滑液囊支原体感染的智能化检测方法及系统 |
| CN114940955B (zh) * | 2022-05-10 | 2023-08-11 | 兆丰华生物科技(南京)有限公司 | 一种鸡毒支原体弱毒疫苗株及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2566833B1 (fr) * | 1984-06-27 | 1986-11-14 | Inst Francais Du Petrole | Methode et perfectionnement aux outils de forage comportant des passages d'eau permettant une grande efficacite du nettoyage du front de taille |
| EP0307976B1 (en) * | 1987-09-18 | 1993-06-23 | Akzo Nobel N.V. | Mycoplasma vaccine |
| US6006134A (en) * | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
| US7599736B2 (en) * | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
| EP1063297B1 (en) * | 1999-06-22 | 2008-12-17 | Korea Kumho Petrochemical Co. Ltd. | Farnesyl pyrophosphate synthase (FPS) derived from seedlings of sunflower (Helianthus annus) |
| JP4723707B2 (ja) * | 1999-12-22 | 2011-07-13 | パナソニック電工株式会社 | 痩身器具 |
| US6885888B2 (en) * | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
| US6922590B1 (en) * | 2000-11-21 | 2005-07-26 | Advanced Bionics Corporation | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion |
| US20020187162A1 (en) * | 2001-04-21 | 2002-12-12 | Geary Steven J. | Use of a live attenuated Mycoplasma gallisepticum strain as a vaccine and vector for the protection of chickens and turkeys from respiratory disease |
| US6721603B2 (en) * | 2002-01-25 | 2004-04-13 | Cyberonics, Inc. | Nerve stimulation as a treatment for pain |
| US7551964B2 (en) * | 2002-03-22 | 2009-06-23 | Leptos Biomedical, Inc. | Splanchnic nerve stimulation for treatment of obesity |
| US7239912B2 (en) * | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
| US7076292B2 (en) * | 2002-04-25 | 2006-07-11 | Medtronic, Inc. | Optical communication of neurostimulation-system information |
| US7217420B2 (en) * | 2002-07-13 | 2007-05-15 | The University Of Georgia Research Foundation, Inc. | Mycoplasma gallisepticum formulation |
| US7155278B2 (en) * | 2003-04-21 | 2006-12-26 | Medtronic, Inc. | Neurostimulation to treat effects of sleep apnea |
| US7312065B2 (en) * | 2003-07-25 | 2007-12-25 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods of use thereof |
| TW200918666A (en) * | 2007-09-11 | 2009-05-01 | Wyeth Corp | Attenuated mycoplasma gallisepticum strains |
-
2008
- 2008-09-09 TW TW097134587A patent/TW200918666A/zh unknown
- 2008-09-09 CL CL2008002675A patent/CL2008002675A1/es unknown
- 2008-09-10 NZ NZ583829A patent/NZ583829A/en not_active IP Right Cessation
- 2008-09-10 UA UAA201002676A patent/UA98506C2/ru unknown
- 2008-09-10 EP EP08830621.2A patent/EP2200640B1/en not_active Not-in-force
- 2008-09-10 BR BRPI0817334A patent/BRPI0817334A8/pt not_active Application Discontinuation
- 2008-09-10 KR KR1020117030531A patent/KR20120014041A/ko not_active Ceased
- 2008-09-10 CN CN200880115552XA patent/CN101896195B/zh not_active Expired - Fee Related
- 2008-09-10 AU AU2008299913A patent/AU2008299913B2/en not_active Ceased
- 2008-09-10 EP EP12192086A patent/EP2564868A1/en not_active Withdrawn
- 2008-09-10 ES ES08830621.2T patent/ES2437593T3/es active Active
- 2008-09-10 KR KR1020107007701A patent/KR101176717B1/ko not_active Expired - Fee Related
- 2008-09-10 WO PCT/US2008/010630 patent/WO2009035644A1/en not_active Ceased
- 2008-09-10 PL PL08830621T patent/PL2200640T3/pl unknown
- 2008-09-10 ME MEP-2010-48A patent/ME00982B/me unknown
- 2008-09-10 US US12/207,750 patent/US7935356B2/en active Active
- 2008-09-10 RU RU2010108641/10A patent/RU2441909C2/ru not_active IP Right Cessation
- 2008-09-10 MX MX2010002866A patent/MX2010002866A/es active IP Right Grant
- 2008-09-10 CA CA2699410A patent/CA2699410C/en not_active Expired - Fee Related
- 2008-09-10 JP JP2010524865A patent/JP5451619B2/ja not_active Expired - Fee Related
- 2008-09-11 AR ARP080103956A patent/AR068418A1/es unknown
-
2010
- 2010-03-11 ZA ZA2010/01740A patent/ZA201001740B/en unknown
- 2010-03-15 CO CO10030400A patent/CO6260102A2/es active IP Right Grant
-
2011
- 2011-03-25 US US13/071,601 patent/US8298552B2/en not_active Expired - Fee Related
-
2012
- 2012-09-26 US US13/626,944 patent/US20130022547A1/en not_active Abandoned
-
2013
- 2013-07-25 US US13/950,910 patent/US20130302373A1/en not_active Abandoned
- 2013-10-31 JP JP2013226338A patent/JP2014027950A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0817334A8 (pt) | Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados | |
| CO6460761A2 (es) | Vacuna viva modificada de mycoplasma bovis mejorada, métodos de producción de vacunas vivas de mycoplasma bovis, vacunas de combinación y métodos de tratamiento | |
| BR112014032636A2 (pt) | Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas | |
| BR112015013700A8 (pt) | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição | |
| BR112012028893A2 (pt) | composições imunoestimuladoras e de vacina | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| BR112012030337A2 (pt) | vacinas compreendendo colesterol e cpg como moléculas veículo-adjuvante exclusivas e uso das mesmas | |
| AR068419A1 (es) | Cepas de mycoplasma atenuadas vivas | |
| ZA202310755B (en) | Immunogenic composition against influenza | |
| BR112012028711A2 (pt) | métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| BR112015000585A8 (pt) | método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| BR112015013004A2 (pt) | molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo | |
| BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
| BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
| UY31437A1 (es) | Vacuna de mycoplasma bovis y métodos de uso de la misma | |
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| BR112017000445A2 (pt) | compósito, processo para preparar um compósito, produto de consumo, usos de um compósito e de uma mescla, e, método para preparar um produto de lavanderia. | |
| BRPI0920622A8 (pt) | vacina contra o vírus da doença equina africana | |
| WO2012009774A3 (pt) | Microrganismos recombinantes, métodos de preparação de linhagens vacinais, antígenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia | |
| BR112017004356A2 (pt) | antígenos de streptococcus agalactiae associados a cepas virulentais em peixes | |
| BR112021026216A2 (pt) | Composições e métodos para o tratamento de infecções fúngicas | |
| BR112012029396A2 (pt) | métodos relativos a um micoplasma atenuado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PAH W LLC (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ZOETIS W LLC (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |